메뉴 건너뛰기




Volumn 28, Issue 11, 2014, Pages

Visceral metastases and prostate cancer treatment: ‘Die hard,’ ‘tough neighborhoods,’ or ‘evil humors’?

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANGIOPOIETIN 2; BEVACIZUMAB; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4; DOCETAXEL; ENZALUTAMIDE; INTERLEUKIN 6; INTERLEUKIN 8; IPILIMUMAB; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN MCL 1; SIPULEUCEL T; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

EID: 84914170525     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (30)

References (46)
  • 1
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 2
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    De Wit, R.2    Berry, W.R.3
  • 3
    • 0034085989 scopus 로고    scopus 로고
    • Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
    • Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-83.
    • (2000) Hum Pathol , vol.31 , pp. 578-583
    • Bubendorf, L.1    Schopfer, A.2    Wagner, U.3
  • 4
    • 84885844885 scopus 로고    scopus 로고
    • Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer
    • abstr 4642
    • Fizazi K, Massard C, Smith MR, et al. Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2012:30(suppl):abstr 4642.
    • (2012) J Clin Oncol , vol.30
    • Fizazi, K.1    Massard, C.2    Smith, M.R.3
  • 5
    • 84898920356 scopus 로고    scopus 로고
    • Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)
    • abstr 2
    • Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014:32(suppl 4):abstr 2.
    • (2014) J Clin Oncol , vol.32
    • Drake, C.G.1    Kwon, E.D.2    Fizazi, K.3
  • 6
    • 84914119103 scopus 로고    scopus 로고
    • The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials
    • abstr 5002
    • Halabi S, Kelly WK, Zhou H, et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. J Clin Oncol. 2014:32(suppl 5):abstr 5002.
    • (2014) J Clin Oncol , vol.32
    • Halabi, S.1    Kelly, W.K.2    Zhou, H.3
  • 7
    • 84878800972 scopus 로고    scopus 로고
    • Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
    • Akfirat C, Zhang X, Ventura A, et al. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol. 2013;230:291-7.
    • (2013) J Pathol , vol.230 , pp. 291-297
    • Akfirat, C.1    Zhang, X.2    Ventura, A.3
  • 8
    • 44449108773 scopus 로고    scopus 로고
    • Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases
    • Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008;25:377-88.
    • (2008) Clin Exp Metastasis , vol.25 , pp. 377-388
    • Morrissey, C.1    True, L.D.2    Roudier, M.P.3
  • 9
    • 0034896088 scopus 로고    scopus 로고
    • Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer
    • Tsushima H, Ito N, Tamura S, et al. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res. 2001;7:1258-62.
    • (2001) Clin Cancer Res , vol.7 , pp. 1258-1262
    • Tsushima, H.1    Ito, N.2    Tamura, S.3
  • 10
    • 44149106165 scopus 로고    scopus 로고
    • Serum markers for prostate cancer: A rational approach to the literature
    • Steuber T, O’Brien MF, Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol. 2008;54:31-40.
    • (2008) Eur Urol , vol.54 , pp. 31-40
    • Steuber, T.1    O’Brien, M.F.2    Lilja, H.3
  • 11
    • 0142008439 scopus 로고    scopus 로고
    • The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer
    • Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21:3573-79.
    • (2003) J Clin Oncol , vol.21 , pp. 3573-3579
    • Kattan, M.W.1    Shariat, S.F.2    Rews, B.3
  • 12
    • 84894085480 scopus 로고    scopus 로고
    • Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
    • Goodman OB, Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34-9.
    • (2014) Prostate Cancer Prostatic Dis , vol.17 , pp. 34-39
    • Goodman, O.B.1    Flaig, T.W.2    Molina, A.3
  • 13
    • 84894074281 scopus 로고    scopus 로고
    • Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    • abstr 5065
    • Loriot Y, Fizazi K, De Bono JS, et al. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. J Clin Oncol. 2013;31(suppl):abstr 5065.
    • (2013) J Clin Oncol , vol.31
    • Loriot, Y.1    Fizazi, K.2    De Bono, J.S.3
  • 14
    • 35948933892 scopus 로고    scopus 로고
    • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
    • Armstrong AJ, Garrett-Mayer ES, Yang TC, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396-403.
    • (2007) Clin Cancer Res , vol.13 , pp. 6396-6403
    • Armstrong, A.J.1    Garrett-Mayer, E.S.2    Yang, T.C.3
  • 15
    • 0038514138 scopus 로고    scopus 로고
    • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    • Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-7.
    • (2003) J Clin Oncol , vol.21 , pp. 1232-1237
    • Halabi, S.1    Small, E.J.2    Kantoff, P.W.3
  • 16
    • 84890980389 scopus 로고    scopus 로고
    • Breathing new life into immunotherapy: Review of melanoma, lung and kidney cancer
    • Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24-37.
    • (2014) Nat Rev Clin Oncol , vol.11 , pp. 24-37
    • Drake, C.G.1    Lipson, E.J.2    Brahmer, J.R.3
  • 17
    • 77954939175 scopus 로고    scopus 로고
    • Prostate cancer as a model for tumour immunotherapy
    • Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-93.
    • (2010) Nat Rev Immunol , vol.10 , pp. 580-593
    • Drake, C.G.1
  • 18
    • 84255197842 scopus 로고    scopus 로고
    • Cancer immunotherapy comes of age
    • Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9.
    • (2011) Nature , vol.480 , pp. 480-489
    • Mellman, I.1    Coukos, G.2    Dranoff, G.3
  • 19
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 20
    • 67650463335 scopus 로고    scopus 로고
    • Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer
    • Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-11.
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 1001-1011
    • Madan, R.A.1    Arlen, P.M.2    Mohebtash, M.3
  • 21
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 22
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O’Day, S.J.2    McDermott, D.F.3
  • 23
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 24
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
    • Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
    • (2013) N Engl J Med , vol.369 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3
  • 25
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
    • (2012) N Engl J Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 26
    • 84880508629 scopus 로고    scopus 로고
    • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study
    • Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813-21.
    • (2013) Ann Oncol , vol.24 , pp. 1813-1821
    • Slovin, S.F.1    Higano, C.S.2    Hamid, O.3
  • 27
    • 84914115379 scopus 로고    scopus 로고
    • Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer
    • Graff JN, Puri S, Bifulco CB, et al. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res. 2014;2:399-403.
    • (2014) Cancer Immunol Res , vol.2 , pp. 399-403
    • Graff, J.N.1    Puri, S.2    Bifulco, C.B.3
  • 28
    • 12244252335 scopus 로고    scopus 로고
    • Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
    • Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728-34.
    • (2005) Clin Cancer Res , vol.11 , pp. 728-734
    • Demaria, S.1    Kawashima, N.2    Yang, A.M.3
  • 29
    • 84870659824 scopus 로고    scopus 로고
    • An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
    • Antonarakis ES, Keizman D, Zhang Z, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012;118:6063-71.
    • (2012) Cancer , vol.118 , pp. 6063-6071
    • Antonarakis, E.S.1    Keizman, D.2    Zhang, Z.3
  • 30
    • 84914119102 scopus 로고    scopus 로고
    • Does tumor microenvironment affect the response of castration resistant prostate cancer to therapy in bone vs visceral metastases?
    • abstr MP49-15
    • Hiader M, Coleman I, Zhang X, et al. Does tumor microenvironment affect the response of castration resistant prostate cancer to therapy in bone vs visceral metastases? Proc Am Urological Assoc Annual Meeting. 2014;4(suppl):abstr MP49-15.
    • (2014) Am Urological Assoc Annual Meeting , vol.4
    • Hiader, M.1    Coleman, I.2    Zhang, X.3
  • 31
    • 84996525854 scopus 로고    scopus 로고
    • Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
    • Yuan J, Zhou J, Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2014; 2:127-32.
    • (2014) Cancer Immunol Res , vol.2 , pp. 127-132
    • Yuan, J.1    Zhou, J.2    Dong, Z.3
  • 32
    • 34447117552 scopus 로고    scopus 로고
    • A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
    • Manning EA, Ullman JG, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13:3951-9.
    • (2007) Clin Cancer Res , vol.13 , pp. 3951-3959
    • Manning, E.A.1    Ullman, J.G.2    Leatherman, J.M.3
  • 33
    • 84964313298 scopus 로고    scopus 로고
    • Bevacizumab plus ipilimumab in patients with metastatic melanoma
    • Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42.
    • (2014) Cancer Immunol Res , vol.2 , pp. 632-642
    • Hodi, F.S.1    Lawrence, D.2    Lezcano, C.3
  • 34
    • 78149298209 scopus 로고    scopus 로고
    • Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha
    • Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827-30.
    • (2010) Science , vol.330 , pp. 827-830
    • Kraman, M.1    Bambrough, P.J.2    Arnold, J.N.3
  • 35
    • 65249138393 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells: Linking inflammation and cancer
    • Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499-506.
    • (2009) J Immunol , vol.182 , pp. 4499-4506
    • Ostrand-Rosenberg, S.1    Sinha, P.2
  • 36
    • 33750807427 scopus 로고    scopus 로고
    • CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
    • Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-405.
    • (2006) J Immunol , vol.177 , pp. 7398-7405
    • Miller, A.M.1    Lundberg, K.2    Ozenci, V.3
  • 37
    • 48849103649 scopus 로고    scopus 로고
    • Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
    • Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254-61.
    • (2008) Clin Cancer Res , vol.14 , pp. 3254-3261
    • Sfanos, K.S.1    Bruno, T.C.2    Maris, C.H.3
  • 38
    • 33744984785 scopus 로고    scopus 로고
    • Th17: An effector CD4 T cell lineage with regulatory T cell ties
    • Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677-88.
    • (2006) Immunity , vol.24 , pp. 677-688
    • Weaver, C.T.1    Harrington, L.E.2    Mangan, P.R.3
  • 39
    • 84862016010 scopus 로고    scopus 로고
    • IL-6/IL-6R as a potential key signaling pathway in prostate cancer development
    • Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2:384-96.
    • (2011) World J Clin Oncol , vol.2 , pp. 384-396
    • Azevedo, A.1    Cunha, V.2    Teixeira, A.L.3    Medeiros, R.4
  • 40
    • 0037372374 scopus 로고    scopus 로고
    • Elevation of cytokine levels in cachectic patients with prostate carcinoma
    • Pfitzenmaier J, Vessella R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211-6.
    • (2003) Cancer , vol.97 , pp. 1211-1216
    • Pfitzenmaier, J.1    Vessella, R.2    Higano, C.S.3
  • 42
    • 0023505508 scopus 로고
    • Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines
    • Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987;84:9233-7.
    • (1987) Proc Natl Acad Sci U S A , vol.84 , pp. 9233-9237
    • Yoshimura, T.1    Matsushima, K.2    Tanaka, S.3
  • 43
    • 84914119101 scopus 로고    scopus 로고
    • Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
    • Oct 29. [Epub ahead of print]
    • Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2013 Oct 29. [Epub ahead of print]
    • (2013) BJU Int
    • Nuhn, P.1    Vaghasia, A.M.2    Goyal, J.3
  • 44
    • 0036310021 scopus 로고    scopus 로고
    • Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma
    • Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125-34.
    • (2002) Am J Pathol , vol.161 , pp. 125-134
    • Huang, S.1    Mills, L.2    Mian, B.3
  • 46
    • 84898920356 scopus 로고    scopus 로고
    • Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)
    • abstr 2
    • Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32(suppl 4):abstr 2.
    • (2014) J Clin Oncol , vol.32
    • Drake, C.G.1    Kwon, E.D.2    Fizazi, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.